HOW INTERNATIONAL PATIENTS
ACCESS CAR-T TRIALS IN CHINA
China's CAR-T clinical trial infrastructure accepts international patients โ but the process requires careful preparation. CancerFax navigates every step, from eligibility to visa to bedside interpretation.
analyticsAt a Glance
- check_circleChina's NMPA oversees all CAR-T trials via the CTR (Clinical Trial Registry) โ international patients can enrol at NMPA-registered sites
- check_circleLeading centres accepting international patients: PUTH Beijing, Ruijin Hospital Shanghai, Xuanwu Hospital, SYSUCC Guangzhou
- check_circleDocumentation required: full medical records, pathology slides, flow cytometry, prior treatment history in structured format
- check_circleCancerFax provides medical summary preparation, eligibility pre-screening, visa support, and real-time interpretation
China's Clinical Trial Framework for CAR-T
All CAR-T clinical trials in China operate under the oversight of the National Medical Products Administration (NMPA) and must be registered in the Chinese Clinical Trial Registry (CTR, chictr.org.cn). This dual registry and oversight system ensures standardised safety monitoring across all approved trial sites.
โChina's CAR-T regulatory framework is now mature enough that international patients are actively welcomed at leading trial centres โ with structured pathways for compassionate use and formal enrolment.โ
NMPA Oversight
The NMPA's Centre for Drug Evaluation (CDE) reviews CAR-T investigational new drug (IND) applications and grants approval for each phase. All protocol amendments and serious adverse event reports must be submitted to NMPA within defined timelines.
Compassionate Use Programmes
For patients who do not meet strict trial eligibility criteria (e.g. too many prior lines, certain comorbidities), many leading Chinese CAR-T centres offer expanded access or compassionate use arrangements โ typically at patient cost โ reviewed case by case.
Chinese CAR-T Centres Accepting International Patients
The following leading centres have established processes for evaluating and enrolling international patients in CAR-T trials. All have international patient departments with English-language coordination capability.
| Hospital | City | CAR-T Targets Active | International Patient Office |
|---|---|---|---|
| Peking University Third Hospital (PUTH) | Beijing | CD19, BCMA, CLDN18.2, GPC3, GPRC5D | Yes โ dedicated international department |
| Ruijin Hospital (Shanghai Jiao Tong University) | Shanghai | CD19, BCMA, GPC3, CLDN18.2 | Yes โ English-language coordination |
| Xuanwu Hospital (Capital Medical University) | Beijing | GBM (EGFRvIII), CD19, BCMA | Yes โ neurosurgery international referrals |
| Sun Yat-sen University Cancer Centre (SYSUCC) | Guangzhou | Solid tumour CAR-T (mesothelin, GD2), CD19 | Yes โ active international oncology programme |
| Tongji Hospital (Huazhong University of Science) | Wuhan | CD19, BCMA, CD22 | Partial โ CancerFax coordination required |
Step-by-Step: How International Patients Access CAR-T Trials in China
The process from first contact to CAR-T infusion typically takes 4โ8 weeks for eligible patients. CancerFax manages every step.
- 1
Step 1 โ Upload and Organise Medical Records
Collect all relevant records: diagnosis pathology report, IHC/molecular testing, complete prior treatment history (lines, dates, doses, responses), current haematology and organ function labs, and any prior CAR-T or cellular therapy history.
- 2
Step 2 โ CancerFax Medical Summary Preparation
CancerFax prepares a structured oncology summary in the format required by Chinese trial sites โ translating records, standardising lab values, and framing the clinical history for the eligibility committee.
- 3
Step 3 โ Eligibility Pre-Screening at Trial Site
The structured summary is submitted to the relevant trial site's principal investigator for eligibility review. CancerFax follows up and communicates the outcome โ typically within 1โ2 weeks.
- 4
Step 4 โ M-Visa Application (Medical Visa)
Once a centre confirms interest or eligibility, the patient applies for a Chinese M-visa (medical treatment visa) with documentation from the treating hospital. CancerFax provides the visa invitation letter template and guides the application.
- 5
Step 5 โ Travel, Leukapheresis, and Manufacturing
For autologous CAR-T: the patient travels to China, undergoes leukapheresis (T-cell collection), and waits 3โ6 weeks in China or returns home during manufacturing. For allogeneic: immediate infusion preparation begins.
- 6
Step 6 โ Lymphodepletion, Infusion, and Monitoring
3โ5 days of lymphodepletion chemotherapy, then CAR-T infusion. Mandatory in-hospital monitoring for 14โ30 days for CRS and ICANS. CancerFax provides bedside interpretation and family support throughout.
Key Numbers for International Patient Access
Understanding the timeline, costs, and logistics involved in accessing CAR-T trials in China helps families plan effectively.
- 4โ8 wksTotal process time from first contact to infusion (autologous)Varies by product type: 3โ6 week manufacturing dominates the timeline for autologous programmes.
- 14โ30 daysMandatory in-hospital monitoring post-infusionAll Chinese CAR-T trial protocols require inpatient monitoring; some centres allow hotel-based monitoring after day 14.
- M-VisaMedical visa required โ not tourist visaChina requires an M-visa (medical treatment visa) for patients receiving treatment; tourist visa use for treatment is not permitted.
Trial-Sponsored vs Patient-Paid: Understanding the Cost Model
The financial model for CAR-T access in China varies significantly by trial type. Understanding this distinction before engaging with a centre prevents unexpected costs.
Sponsor-Funded Trials
- CAR-T product provided free by sponsorThe pharmaceutical or biotech company funding the trial covers manufacturing costs for eligible trial participants.
- Strict eligibility criteria applySponsor-funded trials have precise inclusion/exclusion criteria โ patients must meet all criteria to receive the free product.
- Hospitalisation costs remain patient responsibilityEven in fully sponsored trials, the cost of hospital stay, monitoring, supportive care, and CRS/ICANS management is typically patient-paid.
Patient-Paid / Compassionate Use
- Patient covers CAR-T manufacturing costCompassionate use and named patient programmes require the patient to pay for manufacturing โ typically $50,000โ$150,000 USD for Chinese products.
- Broader eligibility โ more patients qualifyCompassionate use arrangements can accommodate patients who fail strict trial criteria due to prior treatments or comorbidities.
- Full transparency required before committingCancerFax ensures patients receive a complete cost breakdown โ CAR-T manufacturing, hospitalisation, monitoring, and ancillary costs โ before any financial commitment.
Documentation Completeness โ Impact on Eligibility Review Speed
The completeness of a patient's medical documentation directly affects how quickly a Chinese trial site can assess eligibility. Incomplete submissions cause delays of weeks.
Typical Eligibility Review Timeline by Documentation Quality
CancerFax internal data across 200+ cases submitted to Chinese CAR-T centres
- Complete documentation โ days to PI response7โ10 days
- Partial documentation โ days to PI response14โ21 days
- Incomplete โ significant rework required4โ6 weeks
Medical Documentation Checklist for CAR-T Trial Applications
Every document below should be assembled before submitting to a Chinese CAR-T centre. Missing items delay the review significantly and can result in outright rejection without consideration.
| Document | Required Format | Why It Matters |
|---|---|---|
| Pathology report with IHC | Original pathology + English translation | Confirms diagnosis, histology, and target antigen expression (e.g. CD19, CLDN18.2, GPC3) |
| Flow cytometry (for blood cancers) | Most recent โ within 3 months | Confirms antigen expression level (e.g. CD19+ % blasts) โ critical for CAR-T eligibility |
| Complete treatment history | All lines: drug, dates, doses, best response, reason for stopping | Confirms treatment-refractory status required for most CAR-T trial criteria |
| Current full blood count + organ function | Within 4 weeks | Confirms adequate organ function for lymphodepletion and CAR-T infusion safety |
| Imaging (CT/PET) | Most recent โ within 6โ8 weeks | Confirms active measurable disease for trial inclusion |
| Prior CAR-T or cellular therapy records (if any) | Full treatment records | Prior CAR-T or stem cell transplant may affect eligibility for specific trials |
More from the CAR-T Cell Therapy Resource Library
Continue reading about CAR-T access, solid tumour programmes, and preparation for treatment in China.
Frequently Asked Questions โ International CAR-T Access
The most common questions CancerFax receives from international patients and families exploring CAR-T trial access in China.
Practical Questions
Do I need to speak Mandarin to be treated at a Chinese CAR-T centre?
No โ CancerFax provides medical interpretation throughout your stay, including daily rounds, consent processes, CRS/ICANS discussions, and discharge planning. All major partner centres also have English-speaking international patient coordinators. Medical documents submitted for eligibility review are translated by CancerFax before submission.
What type of visa do I need to travel to China for CAR-T treatment?
You need a Chinese M-visa (medical treatment visa), not a tourist L-visa or business F-visa. The M-visa requires a formal invitation letter from the treating hospital in China. CancerFax assists with obtaining this letter from the partner centre once eligibility is confirmed. Visa processing typically takes 2โ3 weeks โ plan accordingly.
Can a family member accompany me during treatment in China?
Yes โ and this is strongly encouraged. One or two family members can travel on accompanying M-visas or L-visas. Having a family member present during the critical 14โ30 day post-infusion monitoring period significantly improves outcomes, as family can alert the medical team to early ICANS symptoms (confusion, word-finding difficulty) that the patient may not self-report.
What happens if I develop serious CRS or ICANS during treatment in China?
All Chinese CAR-T trial sites operate with ICU backup and have tocilizumab and dexamethasone on formulary for CRS and ICANS management respectively. CancerFax ensures that only centres with demonstrated CRS/ICANS management capability and dedicated haematology ICU access are in our partner network. In the event of severe toxicity, CancerFax coordinates real-time communication between the medical team and the patient's family.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Ready to Explore CAR-T Trial Access in China?
CancerFax reviews your complete medical history, prepares a structured oncology summary, and submits it to our partner centres in China for eligibility review โ at no obligation.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.